Cue Biopharma Stock Price on April 30, 2024
| CUE Stock | USD 1.06 0.04 3.92% |
Below is the normalized historical share price chart for Cue Biopharma extending back to January 02, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Cue Biopharma stands at 1.06, as last reported on the 18th of December 2024, with the highest price reaching 1.09 and the lowest price hitting 0.95 during the day.
If you're considering investing in Cue Stock, it is important to understand the factors that can impact its price. Cue Biopharma is dangerous given 3 months investment horizon. Cue Biopharma secures Sharpe Ratio (or Efficiency) of 0.14, which signifies that the company had a 0.14% return per unit of standard deviation over the last 3 months. We are able to break down and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.65% are justified by taking the suggested risk. Use Cue Biopharma risk adjusted performance of 0.1052, and Mean Deviation of 7.89 to evaluate company specific risk that cannot be diversified away.
At present, Cue Biopharma's Liabilities And Stockholders Equity is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 24 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 30 M. . As of December 18, 2024, Price To Sales Ratio is expected to decline to 20.90. In addition to that, Price Earnings Ratio is expected to decline to -2.5. Cue Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 2nd of January 2018 | 200 Day MA 1.2829 | 50 Day MA 1.3256 | Beta 1.796 |
Cue |
Sharpe Ratio = 0.1353
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CUE | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.19 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.65 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Cue Biopharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cue Biopharma by adding it to a well-diversified portfolio.
Price Book 2.5474 | Enterprise Value Ebitda (1.76) | Price Sales 8.0954 | Shares Float 48.2 M | Wall Street Target Price 3.6 |
Cue Biopharma Main Headline on 30th of April 2024
Disposition of 6667 shares by Millar Kerri-ann of Cue Biopha... by Millar Kerri-ann
Filed transaction by Cue Biopharma Officer Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Cue Biopharma Valuation on April 30, 2024
It is possible to determine the worth of Cue Biopharma on a given historical date. On April 30, 2024 Cue was worth 1.4 at the beginning of the trading date compared to the closed value of 1.9. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Cue Biopharma stock. Still, in general, we apply an absolute valuation method to find Cue Biopharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cue Biopharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Cue Biopharma's related companies.
| Open | High | Low | Close | Volume | |
| 1.39 | 1.48 | 1.38 | 1.42 | 155,923 | |
04/30/2024 | 1.40 | 1.98 | 1.37 | 1.90 | 1,261,318 |
| 1.92 | 1.99 | 1.60 | 1.91 | 622,040 |
| Backtest Cue Biopharma | | | Cue Biopharma History | | | Cue Biopharma Valuation | Previous | Next |
Cue Biopharma Trading Date Momentum on April 30, 2024
| On May 01 2024 Cue Biopharma was traded for 1.91 at the closing time. Highest Cue Biopharma's price during the trading hours was 1.99 and the lowest price during the day was 1.60 . The net volume was 622 K. The overall trading history on the 1st of May contributed to the next trading period price growth. The overall trading delta to the next next day price was 0.53% . The overall trading delta to current price is 1.58% . |
Cue Biopharma Fundamentals Correlations and Trends
By evaluating Cue Biopharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Cue financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Cue Biopharma Stock history
Cue Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cue is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cue Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cue Biopharma stock prices may prove useful in developing a viable investing in Cue Biopharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 45.8 M | 30 M | |
| Net Loss | -47.7 M | -50.1 M |
Cue Biopharma Quarterly Net Working Capital |
|
Cue Biopharma Stock Technical Analysis
Cue Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Cue Biopharma Period Price Range
Low | December 18, 2024
| High |
0.00 | 0.00 |
Cue Biopharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Cue Biopharma December 18, 2024 Market Strength
Market strength indicators help investors to evaluate how Cue Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cue Biopharma shares will generate the highest return on investment. By undertsting and applying Cue Biopharma stock market strength indicators, traders can identify Cue Biopharma entry and exit signals to maximize returns
Cue Biopharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Cue Biopharma's price direction in advance. Along with the technical and fundamental analysis of Cue Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cue to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1052 | |||
| Jensen Alpha | 1.54 | |||
| Total Risk Alpha | 0.6162 | |||
| Sortino Ratio | 0.2167 | |||
| Treynor Ratio | 3.64 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |